RxDoctor Payments Data

Rochelle Raymond

Psychiatric/Mental Health · Bad Axe, MINPI 1407404221

Payments from drug & device makers

$1,447in general payments, 2019–2025

Across 75 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$287
  • Alkermes, Inc.$251
  • Teva Pharmaceuticals USA, Inc.$229
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$168
  • Johnson & Johnson$149
  • E.r. Squibb & Sons, L.L.C.$145
  • plus $217 from 6 others

What the payments were for

  • Food & beverage$1,447100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,447 in reported general payments places this provider in the 65th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$21,451
Medicare patients
70
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate24$191,867
RexultiBrexpiprazole68$94,960
Invega SustennaPaliperidone Palmitate12$40,708
Abilify MaintenaAripiprazole13$35,912
Clozapine OdtClozapine39$12,724
TrintellixVortioxetine Hydrobromide25$11,760
Paliperidone ErPaliperidone87$9,168
ConcertaMethylphenidate Hcl12$8,784
Lurasidone Hcl41$6,598
FetzimaLevomilnacipran Hcl13$6,471
Clozapine127$4,615
Fluvoxamine Maleate ErFluvoxamine Maleate13$4,466
VyvanseLisdexamfetamine Dimesylate12$4,292
Haloperidol Decanoate133$4,054
Olanzapine218$3,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna, Concerta$149$241,35848 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$287$130,87281 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$22$16,05237 claims
AbbVieFetzima$54$6,47113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Bad Axe

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →